Overview

First in Human Study of M6223

Status:
Recruiting

Trial end date:
2022-09-14

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), immunogenicity and (if observed) the maximum tolerated dose (MTD) of M6223 as a single agent (Part 1A) and of M6223 combined with bintrafusp alfa [Part 1B, for both the every 2 weeks (Q2W) regimen and the every 3 weeks (Q3W) regimen] in participants with metastatic or locally advanced solid unresectable tumors.

Phase:

Phase 1

Details

Lead Sponsor:

EMD Serono Research & Development Institute, Inc.

Collaborator:

Merck KGaA, Darmstadt, Germany